CVS Lawsuit: DOJ Opioid Claims, Penalties, and Case Status

The CVS opioid lawsuit is a civil case filed by the U.S. Department of Justice in December 2024 accusing the country’s largest pharmacy chain of knowingly filling millions of unlawful controlled-substance prescriptions from October 2013 onward and then billing Medicare, Medicaid, and TRICARE for them. The complaint was unsealed on December 18, 2024, in the U.S. District Court for the District of Rhode Island. CVS has called the allegations a “false narrative” and says it will fight them in court.¹

What the Government Is Alleging

The DOJ’s case rests on two federal statutes. Under the Controlled Substances Act, pharmacists have a “corresponding responsibility” to verify that every controlled-substance prescription has a legitimate medical purpose before dispensing it. The government says CVS made that verification effectively impossible and filled prescriptions its own pharmacists had flagged as suspicious. Under the False Claims Act, the DOJ argues that when CVS sought reimbursement from federal health programs for those unlawful fills, each claim was itself fraudulent.²

The alleged conduct runs from October 17, 2013, to the present and covers CVS locations nationwide. DEA Administrator Anne Milgram said CVS “dispensed large amounts of highly addictive opioid medications to persons they knew had no medical need for them” and “put profits over their obligation to keep their customers safe.”¹

How the Case Started

The lawsuit grew out of a confidential whistleblower complaint filed on October 17, 2019 by Hillary Estright, a former CVS pharmacy manager in Tennessee. Estright alleged that CVS stores were chronically understaffed and that when pharmacists flagged suspicious prescriptions, no system passed those warnings on to other CVS locations serving the same prescribers. After investigating for more than four years, the Justice Department intervened and filed its own complaint under case number 1:22-cv-222.³

Staffing, Speed, and the “Assembly Line”

A central strand of the complaint is that CVS set staffing so low, and performance metrics so demanding, that pharmacists could not meaningfully review the prescriptions they filled. The government describes an “assembly line style of medication preparation” that put throughput ahead of safety.⁴

Internal messages quoted in the filing capture the atmosphere in blunt terms. One employee warned that “safety issues arise when one is dealing with medication and also being rushed to fulfill an order like McDonalds.” A pharmacist called the work “soul crushing” and estimated that each prescription received less than a minute of review.⁵ The DOJ also alleges CVS declined to implement a recommended due-diligence checklist for high-risk opioid prescriptions after estimating it would cost $11 million in additional labor.²

Prescribers CVS Allegedly Kept Filling For

The complaint names specific doctors whose prescriptions CVS pharmacists tried to flag internally. One pharmacist wrote that Dr. Howard Diamond needed to be “investigated and shut down.” An internal alert for Dr. Robert Ritchea read: “DONOT FILL ANY RITCHEA SCRIPTS!” Other prescribers were described in internal communications as “a pill pusher and a drunk” and “the candy man.”⁴ According to the government, CVS did not instruct its pharmacies to stop filling for these prescribers and in some instances told individual stores they could not refuse.

One physician cited in the suit reportedly wrote an estimated 16,000 controlled-substance prescriptions over roughly 21 months, averaging about 25 per day. The filing also highlights so-called “trinity” prescriptions combining an opioid, a benzodiazepine, and the muscle relaxant carisoprodol, a mixture considered a hallmark of abuse. In one 2020 example, a single CVS location dispensed 270 opioid tablets, 90 diazepam tablets, and 90 carisoprodol tablets to one patient in a single day.⁵

Patient Deaths in the Complaint

The filing references 10 patient deaths tied to CVS fills, according to CNN’s reporting.⁶ One Virginia patient in 2018 received high doses of oxycodone and morphine that overlapped with alprazolam, a combination CVS internally called the “double threat.” The patient died of a mixed-drug overdose four days after a final CVS fill, and the prescribing doctor later pleaded guilty to illegally prescribing the medications, admitting they served no legitimate medical purpose.⁴

A second patient, identified as “Patient #2,” received 201 alprazolam tablets over three months, an excess supply of 166 tablets, while filling opioid prescriptions from the same doctor at other pharmacies. That patient died of a mixed overdose 10 days after their last CVS pickup.⁵

How CVS Is Responding

CVS said it “strongly disagrees with the allegations and false narrative” in the DOJ’s complaint and intends to “defend ourselves vigorously.”⁷ Its defense breaks down along a few lines.

The company argues that every prescription at issue was for an FDA-approved medication written by a practitioner the government itself had licensed and authorized. It says the DOJ is imposing a “shifting standard for pharmacy practice” not grounded in any existing statute or regulation, and that the DEA has repeatedly declined to give pharmacies clear quantitative guidance on when to refuse to fill. CVS also says its pharmacists face a serious dilemma, exposed on one side to liability for filling and on the other to lawsuits from patients and prescribers who accuse the chain of refusing legitimate prescriptions.

On its own compliance record, CVS points to a program it says has blocked controlled-substance prescriptions from more than 1,250 practitioners of concern, roughly 600 of whom remain licensed. The company also cites algorithm-based forgery detection, system-wide checks for active DEA registrations, and pharmacist access to state prescription drug monitoring databases.⁷

What CVS Could Owe

The False Claims Act allows civil penalties of $5,500 to $23,607 per claim, with the higher figures applying to claims filed after November 2015, plus treble damages on the amount by which the government was defrauded.⁵ Because the alleged conduct spans more than a decade of nationwide dispensing, the potential exposure is very large. The DOJ is also seeking injunctive relief that could force changes to CVS’s compliance programs.¹

Where the Case Stands

As of mid-2026, the lawsuit is still in its early stages, with no trial date set. CVS filed a motion to dismiss in April 2025, but the parties repeatedly asked to continue the hearing. In March 2026, District Judge Melissa R. DuBose denied the motion without prejudice, meaning CVS can refile, and noted the repeated delays. Discovery has been stayed since February 2025. The most recent docket entry was filed on May 15, 2026.⁸

How Walgreens Resolved a Similar Case

The CVS case is not the only one of its kind. In April 2025, Walgreens agreed to a $300 million civil settlement to resolve nearly identical DOJ allegations that it filled millions of invalid opioid prescriptions and billed federal programs for them. The Walgreens deal was described as the largest Controlled Substances Act resolution in the history of the Northern District of Illinois and included a seven-year compliance agreement with the DEA and a five-year Corporate Integrity Agreement with the HHS Office of Inspector General. It resolved four separate whistleblower cases.⁹ Whether the CVS case follows that path or heads toward trial is still open.

How This Case Differs From the 2022 State Settlement

One point of confusion worth clearing up: the federal DOJ lawsuit is separate from the multistate settlement CVS reached in late 2022. In that earlier deal, CVS agreed to pay nearly $5 billion over 10 years to resolve claims by state attorneys general that it contributed to the opioid crisis, without admitting wrongdoing. That agreement also required court-ordered improvements to how CVS handles opioid prescriptions.¹⁰¹¹ CVS has argued that the issues in the DOJ complaint were “largely resolved” by that settlement. The federal government disagrees, and the current case remains active on its own docket.

1
U.S. Department of Justice. Justice Department Files Nationwide Lawsuit Alleging CVS Knowingly Dispensed Controlled Substances
2
Legal Dive. CVS Dispensed Opioid Drugs Unlawfully in Profit Push, U.S. Suit Alleges
3
Insurance Journal. DOJ Files Nationwide Lawsuit Against CVS Over Opioid Dispensing
4
U.S. Department of Justice. Consolidated Complaint in Intervention
5
Rhode Island Current. DOJ Suit Claims CVS Ignored Red Flags, Dispensed Opioids From Dangerously Understaffed Pharmacies
6
CNN. DOJ Sues CVS Over Opioid Dispensing
7
CVS Health. Our Opioid Response
8
CourtListener. United States of America v. CVS Health Corporation
9
U.S. Department of Justice. Walgreens Agrees to Pay $300M for Illegally Filling Unlawful Opioid Prescriptions
10
NPR. CVS and Walgreens Agree to Opioid Crisis Settlement
11
New York Attorney General. Attorney General James Secures Over $10 Billion From CVS and Walgreens for Communities